BioSpace News Archive

Coherus BioSciences, Inc., reviewed corporate events and reported financial results for the third quarter and nine months ended September 30, 2020.

Released Very Positive Phase 2 Data for IMU-838 in Relapsing-Remitting Multiple Sclerosis; Company to Submit End-of-Phase 2 Meeting Requests to Regulatory Authorities at the End of Q1 2021

Luminex Corporation announced results for its third quarter ended September 30, 2020.

Avidity Biosciences, Inc. announced that Sarah Boyce, President and Chief Executive Officer, will be presenting at the Credit Suisse 29th Annual Virtual Healthcare Conference 2020 on Thursday, November 12th, 2020 at 8:45am PST.

ViewRay, Inc. announced financial results for the third quarter ended September 30, 2020.

Inhibrx, Inc., a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, announced that the Company will be presenting at the following upcoming virtual investor and scientific conferences:

Acquired MVE Biological Solutions and CRYOPDP advancing Cryoport’s position as the global leader in temperature-controlled supply chain solutions for the life sciences industry

Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, today announced that 16 abstracts, including three oral presentations from the companies’ combined immuno-oncology research and development programs, have been accepted for presentation at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition

OSAKA, Japan--( BUSINESS WIRE )-- Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it will present 22 company-sponsored abstracts at the 62nd American Society of Hematology (ASH) Annual Meeting,

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces that it will host a virtual Key Opinion Leader (KOL) event to review data presented from two ongoing clinical trials of MRx0518, the Company’s lead immuno-oncology single strain Live Biotherapeutic, as both a neoadjuvant monotherapy and combi